THY1 and acute myeloid leukemia: AML-derived MSCs (AML-MSCs) exhibit some differences compared to MSCs from healthy donors; although AML-MSCs express CD90, CD73, and CD44 levels that are similar to those of a healthy counterpart, a decrease in chemoattractant protein-1 levels is observed [127].